Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)
- 1 May 2002
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 143 (5) , 847-853
- https://doi.org/10.1067/mhj.2002.122173
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty StudyAmerican Heart Journal, 2001
- Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseJournal of the American College of Cardiology, 2000
- “Rescue” abciximab for complicated percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1998
- “Rescue” Utilization of Abciximab for the Dissolution of Coronary Thrombus Developing as a Complication of Coronary AngioplastyJournal of the American College of Cardiology, 1997
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Relation Between Activated Clotting Time During Angioplasty and Abrupt ClosureCirculation, 1996
- Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction AnginaNew England Journal of Medicine, 1995
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1988
- Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapyThe American Journal of Medicine, 1987